Perhaps this is what President Trump is exploring. Reuters reports:
Drugmakers have been warned that the Trump Administration is considering linking U.S. medicine prices to lower amounts paid by other developed countries, according to two company sources who called the option the pharmaceutical industry’s top concern.
Both sources, who were not authorized to speak publicly, said they expected the policy to come from the agency that oversees Medicare and Medicaid health programs.
…any such policy was more concerning to the industry than other government moves under discussion, which include tariffs on imported medicines. The first source said it is the biggest “existential threat to the industry and U.S. biosciences innovation.”
President Trump previously proposed the use of international reference pricing in his first term, but the proposal was blocked by the courts as one judge claimed that the rule had been “rushed…without giving the public a chance to comment, in violation of federal law.” The American First Policy Institute published a white paper (“Put Americans First by Ending Global Freeloading“) advocating international reference pricing; thus, the topic is likely on the Trump agenda.
